Tagrisso (osimertinib)

If you have any questions about TAGRISSO CONNECT or would like to speak to an AstraZeneca representative, please complete the form below. Fields marked with * are mandatory.

Note: Your personal details will not be used for any promotional purposes unless you choose to opt in to promotional content by checking the box below, more details can be found in our Privacy Policy

Submit a question Request a meeting Join our mailing list

Submit a question

Title

First Name

Last Name

Role

NHS Organisation

Email Address

Phone number

NHS Organisation Address

NHS Organisation City

NHS Organisation Postcode

How would you prefer to be contacted?

Email Phone

What is your enquiry?

By opting in to AstraZeneca's mailing list, you will receive both promotional and/or non promotional emails, including invitations to webinars and meetings relating to our disease areas and medicines. If you wish to opt in, please tick the checkbox below.

Please note that AstraZeneca UK must verify your contact details against our healthcare professional contact information database. If your contact details are available within this database, an AstraZeneca UK colleague will send you an email to allow you to confirm your opt-in status to receiving future emails. If your contact details are not available within the database, an AstraZeneca UK colleague will contact you to advise how you can be added to the database and confirm your opt-in status.

If you have elected to receive information about our products or services, or those of other AstraZeneca companies, and wish to opt out of receiving such information, then you can do so by sending an email to Privacyrequests@astrazeneca.com.

You should clearly state on all communications: your name, username (if any), registration details (if any), and the name of this website (if any). There is also an unsubscribe link at the bottom of all of our non-promotional and promotional emails that can be clicked if you wish to opt out.

I hereby consent to receive e-mail(s) from AstraZeneca UK. These e-mails may contain non-promotional and/or promotional content.

Adverse reactions reported	TAGRISSO		TAGRISSO with pemetrexed and platinum-based chemotherapy
Adverse reactions reported	CIOMS descriptor/ overall frequency (all CTCAE grades)	Frequency of CTCAE grade 3 or higher	CIOMS descriptor/ overall frequency (all CTCAE grades)	Frequency of CTCAE grade 3 or higher
Blood and lymphatic system disorders
Aplastic anaemia	Rare (0.06%)	0.06%	0%	0%
Leukopenia	Common (5.4%)	0.4%	Very common (12.7%)	2.9%
Lymphopenia	Common (1.7%)	0.2%	Common (2.5%)	1.1%
Thrombocytopenia	Common (7.6%)	0.6%	Very common (18.5%)	6.9%
Neutropenia	Common (6%)	0.9%	Very common (24.6%)	13.4%
Metabolism and nutrition disorders
Decreased appetite	Very common (19%)	1.2%	Very common (31%)	2.9%
Eye disorders
Keratitis	Uncommon (0.6%)	0.06%	Uncommon (0.7%)	0%
Cardiac disorders
Cardiac failure	Uncommon (0.5%)	0.2%	Common (1.8%)	1.1%
Respiratory, thoracic and mediastinal disorders
Epistaxis	Common (6%)	0%	Common (7%)	0.4%
Interstitial lung disease	Common (4.0%)	1.4%	Common (3.3%)	0.7%
Gastrointestinal disorders
Diarrhoea	Very common (47%)	1.4%	Very common (43%)	2.9%
Stomatitis	Very common (24%)	0.4%	Very common (31%)	0.4%
Skin and subcutaneous tissue disorders
Rash	Very common (46%)	0.8%	Very common (49%)	2.5%
Paronychia	Very common (34%)	0.4%	Very common (27%)	0.7%
Dry skin	Very common (32%)	0.1%	Very common (24%)	0%
Pruritus	Very common (17%)	0.06%	Common (8%)	0%
Alopecia	Common (5%)	0%	Common (9%)	0%
Palmar-plantar erythrodysaesthesia syndrome	Common (2.1%)	0%	Common (5%)	0%
Urticaria	Common (1.9%)	0.1%	Common (1.4%)	0.4%
Skin hyperpigmentation	Common (1.0%)	0%	Common (2.5%)	0%
Erythema multiforme	Uncommon (0.3%)	0%	Common (1.4%)	0.7%
Cutaneous vasculitis	Uncommon (0.2%)		0%	0%
Stevens-Johnson syndrome	Rare (0.02%)		0%	0%
Toxic Epidermal Necrolysis	Not known		0%	0%
Investigations
Left ventricular ejection fraction decreased	Common (4.2%)		Common (8%)
QTc interval prolongation	Common (1.1%)		Common (1.8%)
Blood creatine phosphokinase increased	Common (1.9%)	0.3%	Common (3.3%)	1.1%
Investigations (Findings based on test results presented as CTCAE grade shifts)
Leucocytes decreased	Very common (65%)	1.8%	Very common (88%)	20%
Lymphocytes decreased	Very common (64%)	8%	Very common (78%)	16%
Platelet count decreased	Very common (53%)	1.3%	Very common (85%)	16%
Neutrophils decreased	Very common (36%)	4.0%	Very common (85%)	36%
Blood creatinine increased	Common (9%)	0.2%	Very common (22%)	0.4%
Musculoskeletal and connective tissue disorders
Myositis	Uncommon (0.2%)	0%	0%	0%